2024
Risk factors and outcomes after surgery for malignant neoplasm of the parotid gland: An ACS-NSQIP study
Knoedler L, Knoedler S, Hoch C, Safi A, Wollenberg B, Alfertshofer M, Pomahac B, Kauke-Navarro M, Clune J. Risk factors and outcomes after surgery for malignant neoplasm of the parotid gland: An ACS-NSQIP study. Journal Of Plastic Reconstructive & Aesthetic Surgery 2024, 101: 264-274. PMID: 39448324, DOI: 10.1016/j.bjps.2024.09.067.Peer-Reviewed Original ResearchBlood urea nitrogenRisk factorsRenal failureParotid glandMalignant neoplasmsAmerican College of Surgeons National Surgical Quality Improvement Program databaseSurgeons National Surgical Quality Improvement Program databaseAssociated with higher creatinineNational Surgical Quality Improvement Program databaseMicrosurgical proceduresPre-operative risk factorsQuality Improvement Program databaseRisk of postoperative adverse eventsBlood urea nitrogen levelsHigher ASA classPostoperative adverse eventsOccurrence of complicationsPost-surgical outcomesTumor resectionComplication rateFlap surgeryPostoperative outcomesACS-NSQIPASA classHigher creatinineAdvancements in facial implantology: a review of hydroxyapatite applications and outcomes
Kauke-Navarro M, Knoedler L, Knoedler S, Safi A. Advancements in facial implantology: a review of hydroxyapatite applications and outcomes. Frontiers In Surgery 2024, 11: 1409733. PMID: 39092153, PMCID: PMC11291363, DOI: 10.3389/fsurg.2024.1409733.Peer-Reviewed Original ResearchFacial skeletal reconstructionLong-term safetySkeletal reconstructionFacial balanceTumor resectionCraniofacial surgeryAesthetic resultsFacial implantsReconstructive surgeryWeb of Science databasesInclusion criteriaPatient outcomesPatient satisfactionPatientsImplant integrationSystematic reviewSurgeryFacial reconstructionHAP implantsOutcomesGoogle ScholarScience databasesEfficacyHydroxyapatite applicationImplantationHealthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review
de Beur S, Dahir K, Imel E, Zanchetta M, Williams A, Li Z, Webb N, Crowe V, Johnson B, Carpenter T. Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review. The Journal Of Clinical Endocrinology & Metabolism 2024, 110: 102-113. PMID: 38913723, PMCID: PMC11651676, DOI: 10.1210/clinem/dgae431.Peer-Reviewed Original ResearchTumor-induced osteomalaciaHealthcare resource useResection outcomesCase reportHigher probability of tumor recurrenceSecrete fibroblast growth factor 23Probability of tumor recurrenceAssociated with tumor-induced osteomalaciaFibroblast growth factor 23Symptoms to diagnosisHealthcare resource burdenTumor recurrenceParaneoplastic syndromeTumor resectionAssociated with greater usePharmacological treatmentDisease characteristicsImaging testsPatientsMusculoskeletal symptomsTargeted literature reviewResource useOrthopedic surgeryProgressive disabilityMean timeFrom standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases
Knoedler L, Huelsboemer L, Hollmann K, Alfertshofer M, Herfeld K, Hosseini H, Boroumand S, Stoegner V, Safi A, Perl M, Knoedler S, Pomahac B, Kauke-Navarro M. From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases. Frontiers In Immunology 2024, 15: 1276306. PMID: 38715609, PMCID: PMC11074450, DOI: 10.3389/fimmu.2024.1276306.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHead and neck cancerBreast cancerMonoclonal antibodiesCheckpoint inhibitorsSkin cancerReconstructive surgeryNon-surgical treatment strategiesProlonged progression-free survivalSuboptimal treatment plansProgression-free survivalNon-surgical therapySurgical tumor resectionImpaired patient outcomeStandardized treatment algorithmSurgical therapy planningAnti-cancer strategyUnresectable tumorsConventional chemotherapyRemission rateTumor resectionCurative therapyTargeted therapyNeck cancerOncology cases
2023
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.Peer-Reviewed Original ResearchConceptsProgression-free survivalSomatostatin receptor type 2PFS-6Stable diseaseOverall survivalIntracranial meningiomasSingle-arm phase II clinical studyMedian progression-free survivalPhase II clinical studyImaging biomarkersCourse of radiationReceptor type 2Multicenter clinical trialMacdonald criteriaMedian OSRadiographic responseProgressive meningiomasTumor measurementsTumor resectionMedian agePrimary endpointRadiotherapeutic interventionSecondary endpointsMedical therapyAdult patientsEPCO-37. DISSECTING GBM EVOLUTION FOLLOWING STANDARD-OF-CARE BY LARGE-SCALE LONGITUDINAL SINGLE NUCLEUS RNA-SEQUENCING
Nomura M, Spitzer A, Johnson K, Garofano L, Nehar-Belaid D, Oh Y, Anderson K, Najac R, Bussema L, Varn F, D’Angelo F, Chowdhury T, Migliozzi S, Park J, Ermini L, Golebiewska A, Niclou S, Das S, Paek S, Moon H, Mathon B, Di Stefano A, Bielle F, Laurenge A, Sanson M, Tanaka S, Saito N, Keir S, Ashley D, Huse J, Yung W, Lasorella A, Iavarone A, Verhaak R, Suva M, Tirosh I. EPCO-37. DISSECTING GBM EVOLUTION FOLLOWING STANDARD-OF-CARE BY LARGE-SCALE LONGITUDINAL SINGLE NUCLEUS RNA-SEQUENCING. Neuro-Oncology 2023, 25: v132-v132. PMCID: PMC10639295, DOI: 10.1093/neuonc/noad179.0499.Peer-Reviewed Original ResearchSingle-nucleus RNA sequencingLarge-scale longitudinal cohortTME compositionRecurrent samplesGood clinical courseInitial tumor resectionMajority of patientsTumor microenvironment cellsPrimary tumor samplesMGMT methylation statusTME changesClinical courseRNA sequencingTherapy failureLikely respondersTumor resectionDisease progressionNucleus RNA sequencingLongitudinal cohortReciprocal increaseTumor samplesMicroenvironment cellsMalignant cell fractionGlioblastomaRecurrenceFunctional MRI in Neuro-Oncology: State of the Art and Future Directions.
Pasquini L, Peck K, Jenabi M, Holodny A. Functional MRI in Neuro-Oncology: State of the Art and Future Directions. Radiology 2023, 308: e222028. PMID: 37668519, PMCID: PMC10546288, DOI: 10.1148/radiol.222028.Peer-Reviewed Original ResearchConceptsFunctional MRIClinical functional MRIAwake brain surgeryEloquent cortexStudy human brain functionHuman brain functionRegions of activationNeuro-oncologyFunctional neuroanatomyFMRI mapsPatients' performanceBrain functionEloquent cortical areasNeurovascular uncouplingCortical areasPlanning of patientsBrain mappingCortexIntraoperative brain mappingTumor resectionSurgical approachPatient complianceFuture directionsPatient preparationHand movementsVascular steal and associated intratumoral aneurysms in highly vascular brain tumors: illustrative case
Hong C, Marianayagam N, Morales-Valero S, Barak T, Tabor J, O’Brien J, Huttner A, Baehring J, Gunel M, Erson-Omay E, Fulbright R, Matouk C, Moliterno J. Vascular steal and associated intratumoral aneurysms in highly vascular brain tumors: illustrative case. Journal Of Neurosurgery Case Lessons 2023, 5: case22512. PMID: 36880509, PMCID: PMC10550659, DOI: 10.3171/case22512.Peer-Reviewed Original ResearchVascular brain tumorsVascular stealIntratumoral aneurysmBrain tumorsAdditional vascular imagingRight ophthalmic arteryMaximal safe resectionDiagnostic cerebral angiographyMinimal blood lossVascular steal phenomenonOpen tumor resectionDural-based lesionsSteal phenomenonBlood lossCerebral angiographyClinical suspicionNeurological symptomsOphthalmic arterySurgical strategySafe resectionVascular tumorsBlurred visionEndovascular embolizationTomography angiographyTumor resection
2022
CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY
Kurz S, Zan E, Cordova C, Barbaro M, Troxel A, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY. Neuro-Oncology 2022, 24: vii85-vii85. DOI: 10.1093/neuonc/noac209.322.Peer-Reviewed Original ResearchSomatostatin receptor 2Progression-free survivalPhase II studyPFS-6Interim analysis resultsII studyIntracranial meningiomasClinical trialsMulticenter phase II studySomatostatin receptor 2 expressionInterim analysisPET-MRITreatment-limiting toxicityAggressive clinical courseCourse of radiationPET-MR imagingMethylation subclassesRadiotherapeutic optionsStable diseaseProgressive meningiomasOverall survivalNeuroendocrine tumorsSSTR2 expressionTumor measurementsTumor resectionNCOG-46. PERSONALIZED, PARCEL-GUIDED RTMS FOR NEURO-REHABILITATION AFTER TUMOR NEUROSURGERY: SAFETY AND PROOF OF CONCEPT
Yeung J, Tang J, Holle J, Teo C, Sughrue M. NCOG-46. PERSONALIZED, PARCEL-GUIDED RTMS FOR NEURO-REHABILITATION AFTER TUMOR NEUROSURGERY: SAFETY AND PROOF OF CONCEPT. Neuro-Oncology 2022, 24: vii207-vii208. DOI: 10.1093/neuonc/noac209.797.Peer-Reviewed Original ResearchRepetitive transcranial magnetic stimulationUpper Extremity Function ScaleLower Extremity Functional ScaleRTMS treatmentBeck Depression InventoryNeurological disordersDepression InventoryNeuropsychiatric disordersNeuro-rehabilitationPost-operative neurological deficitsTranscranial magnetic stimulationQuality of lifeNon-significant trendMultiple cortical targetsFunctional connectivity approachNon-invasive toolEuroQol qualityNeuropsychiatric questionnaireTumor neurosurgeryNeurological deficitsRetrospective reviewPineal cystsPrimary tumorSurgical removalTumor resectionAdjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
Tan W, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly J. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. European Urology 2022, 83: 497-504. PMID: 35999119, DOI: 10.1016/j.eururo.2022.08.003.Peer-Reviewed Original ResearchConceptsIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancerDisease-free survivalAdverse eventsBladder cancerMitomycin CChemotherapy instillationOpen-labelControl armAdjuvant intravesical chemotherapyProgression-free survivalPhase 2 randomised controlled trialIntention-to-treat analysisLow gradePer-protocol analysisChemohyperthermia groupIntravesical chemotherapyUrinary cytologyHeated chemotherapyOverall survivalWeekly instillationsTumor resectionPrimary endpointRandomised controlled trialsChemohyperthermiaCriteria for Cerebrospinal Fluid Diversion in Retractorless Sphenoid Wing Meningioma Surgery: A Technical Report
Vetsa S, Nadar A, Vasandani S, Gorelick E, Bungard J, Barak T, Fulbright RK, Marianayagam NJ, Moliterno J. Criteria for Cerebrospinal Fluid Diversion in Retractorless Sphenoid Wing Meningioma Surgery: A Technical Report. Journal Of Neurological Surgery Reports 2022, 83: e100-e104. PMID: 36060292, PMCID: PMC9439877, DOI: 10.1055/s-0042-1753518.Peer-Reviewed Original ResearchSphenoid wing meningiomaBrain retractionCerebrospinal fluidYale-New Haven HospitalExtent of resectionCerebrospinal fluid diversionLumbar drain placementNew Haven HospitalCritical neurovascular structuresLD placementProximal sylvian fissureCSF releaseRetractorless surgeryHospital staySurgical complicationsConsecutive patientsVascular encasementAssociated edemaDrain placementTumor resectionMeningioma surgerySurgical challengeSylvian fissureMAIN OUTCOMECarotid cisternResponse to "Letter to the Editor. The weight of functional MRI to predict surgery-induced risk after tumor resection: enough to be safe?"
Połczyńska M, Benjamin C, Bookheimer S. Response to "Letter to the Editor. The weight of functional MRI to predict surgery-induced risk after tumor resection: enough to be safe?". Journal Of Neurosurgery 2022, 137: 314-315. PMID: 39314541, PMCID: PMC11419400.Peer-Reviewed Original ResearchTumor resectionFunctional MRI
2021
Glioblastoma radiomics to predict survival: Diffusion characteristics of surrounding nonenhancing tissue to select patients for extensive resection
Pasquini L, Di Napoli A, Napolitano A, Lucignani M, Dellepiane F, Vidiri A, Villani V, Romano A, Bozzao A. Glioblastoma radiomics to predict survival: Diffusion characteristics of surrounding nonenhancing tissue to select patients for extensive resection. Journal Of Neuroimaging 2021, 31: 1192-1200. PMID: 34231927, DOI: 10.1111/jon.12903.Peer-Reviewed Original ResearchConceptsYear old patientSurvival stratificationOlder patientsRadiomic featuresExtent of resectionImprove patient selectionPrimary CNS neoplasmsCox regression modelsStandard of careLogistic regression analysisT-testNonenhancing tissueTumor resectionExtensive surgeryStandard therapyMRI pre-Patient selectionCNS neoplasmsGlioblastoma patientsMRI featuresRadiomics modelResectionEnhancing portionTreatment protocolsRisk factorsHemorrhage Into a Subependymal Giant Cell Astrocytoma in an Adult With Tuberous Sclerosis
Barbiero FJ, Huttner AJ, Fulbright RK, Baehring JM. Hemorrhage Into a Subependymal Giant Cell Astrocytoma in an Adult With Tuberous Sclerosis. The Neurologist 2021, 26: 122-124. PMID: 34190204, DOI: 10.1097/nrl.0000000000000338.Peer-Reviewed Original ResearchConceptsIntracranial hemorrhageMagnetic resonance imaging (MRI) brainSubependymal giant cell astrocytomaCentral nervous system tumorsYoung adultsLife-threatening complicationsGiant cell astrocytomaNervous system tumorsTuberous sclerosis complexForamen of MonroRare genetic disorderGerm-line mutationsUncommon causeHematoma evacuationDiagnostic delaySpontaneous hemorrhageUnusual causeSubependymal nodulesSurveillance imagingSkin changesTumor resectionSystem tumorsAdenoma sebaceumTuberous sclerosisSkin lesionsOptimal timing of post-operative enoxaparin after neurosurgery: A single institution experience
Briggs RG, Lin YH, Dadario NB, Young IM, Conner AK, Xu W, Tanglay O, Kim SJ, Fonseka RD, Bonney PA, Chakraborty AR, Nix CE, Flecher LR, Yeung JT, Teo C, Sughrue ME. Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience. Clinical Neurology And Neurosurgery 2021, 207: 106792. PMID: 34233235, DOI: 10.1016/j.clineuro.2021.106792.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisLower extremity deep vein thrombosisExtremity deep vein thrombosisIntracranial tumor resectionVenous thromboembolismAnticoagulant prophylaxisProphylactic enoxaparinTumor resectionImmediate post-operative periodMultivariate binomial logistic regression analysisNon-anticoagulation groupSingle institution experiencePost-operative periodPossible risk factorsPost-operative brain tumor patientsEvidence-based protocolsBrain tumor patientsLogistic regression analysisHigh-grade gliomasBinomial logistic regression analysisVTE complicationsElective craniotomyMedical comorbiditiesPulmonary embolismAdult patientsTumor location and reduction in functional MRI estimates of language laterality
Połczyńska MM, Beck L, Kuhn T, Benjamin CF, Ly TK, Japardi K, Cavanagh L, Bookheimer SY. Tumor location and reduction in functional MRI estimates of language laterality. Journal Of Neurosurgery 2021, 135: 1674-1684. PMID: 33799298, PMCID: PMC8909357, DOI: 10.3171/2020.9.jns202036.Peer-Reviewed Original ResearchRight hemisphere tumorsAnterior tumorsHemisphere tumorsLaterality indexLanguage lateralityBroca's areaFMRI laterality indicesLeft hemisphere tumorsPosterior ROIsWhole-brain levelPosterior tumorsTumor locationTumor resectionPreoperative fMRIInferior frontal gyrusTumor groupLanguage cortexBrain tumorsPatientsNumerous confoundersTumor hemisphereConfoundersRegion of interestLeft inferior frontal gyrusTumors
2020
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Herbst R, Tsuboi M, John T, Grohé C, Majem M, Goldman J, Kim S, Marmol D, Rukazenkov Y, Wu Y. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Journal Of Clinical Oncology 2020, 38: lba5-lba5. DOI: 10.1200/jco.2020.38.18_suppl.lba5.Peer-Reviewed Original ResearchDisease-free survivalComplete tumor resectionDFS hazard ratioAdjuvant chemotherapyData cutoffHazard ratioOverall survivalTumor resectionAdjuvant osimertinibDFS ratesEGFRm NSCLCEGFR-TKISafety profileEGFR mutation-positive NSCLCEffective new treatment strategyResected stage IISafety of osimertinibEarly-stage diseaseMutation-positive NSCLCNew treatment strategiesUnplanned interim analysisEligible ptsIIIA NSCLCNSCLC presentPS 0/1Long-term follow up outcomes of surgical resection of Shamblin Ⅱ/Ⅲ carotid body tumor: a single center analysis
Zhang W, Liu F, Wang L, Guo D, Xu X, Chen B, Jiang J, Yang J, Shi Z, Fu W. Long-term follow up outcomes of surgical resection of Shamblin Ⅱ/Ⅲ carotid body tumor: a single center analysis. Chinese Journal Of General Surgery 2020, 35: 195-198. DOI: 10.3760/cma.j.cn113855-20191209-00724.Peer-Reviewed Original ResearchCarotid body tumorTumor sizeNeurological complicationsShamblin IISurgical resectionBlood lossProcedure timePatient died of multi-organ failureMalignant carotid body tumorLength of hospital stayVascular interventionsProcedural blood lossMulti-organ failureLong-term prognosisPatient diedTumor resectionBody tumorsPerioperative mortalitySurgical outcomesHospital stayResectionShamblinTumorPatientsComplications
2019
Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy
Yanishevski D, McCarville M, Doubrovin M, Spiegl H, Zhao X, Lu Z, Federico S, Furman W, Murphy A, Davidoff A. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy. Journal Of Pediatric Surgery 2019, 55: 130-134. PMID: 31685267, DOI: 10.1016/j.jpedsurg.2019.09.067.Peer-Reviewed Original ResearchConceptsNon-amplified tumorsNeoadjuvant chemotherapyHigh-risk neuroblastomaCurie scoreTumor responseMYCN amplificationGreater mean percentage reductionHigh-risk neuroblastoma patientsMetastatic disease responsePrimary tumor responsePercentage of patientsPrimary tumor volumeAggressive clinical phenotypeMean percentage reductionPercentage volume changeLocoregional diseaseSurgical resectionMetastatic sitesNeuroblastoma patientsPrimary tumorTumor resectionTumor volumeCT scanMYCN statusChemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply